LPCN - Lipocine competitor prevails in patent infringement lawsuit for Jatenzo

The U.S. District Court of Delaware has granted Clarus Therapeutics' motion for summary judgment against Lipocine (LPCN) for failure to provide adequate written description of Lipocine's asserted patent claims.In his decision, which gives Clarus an unequivocal win, Judge William C. Bryson found all of the asserted Lipocine patent claims invalid.Clarus's defense of inequitable conduct, to be tried before Judge Bryson, remains pending, and its disposition is expected to be addressed by Clarus and the Court at a future date. The action for patent infringement was brought by Lipocine against Clarus in April 2019, arising out of Clarus's marketing of Jatenzo, an oral testosterone replacement product approved by the FDA.Lipocine previously dismissed infringement allegations against Clarus on two other Lipocine patents.

For further details see:

Lipocine competitor prevails in patent infringement lawsuit for Jatenzo